Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02974621
Recruitment Status : Active, not recruiting
First Posted : November 28, 2016
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 31, 2022
Estimated Study Completion Date : May 31, 2022